Dyne and Sarepta Shares Fall After Novartis Trial Fails
Shares of Dyne Therapeutics and Sarepta tumbled after a Novartis muscle disease treatment failed in a late stage trial. The setback raised concerns among investors regarding similar rare disease therapies currently in development.
Xurve View
Insights:
Xurve View
Dyne Therapeutics shares slumped nearly 18% on Tuesday following a clinical trial failure by Novartis AG-REG that weighed across muscle disease developers. The drop highlights growing investor anxiety over therapeutic programs targeting myotonic dystrophy type 1. The rare genetic condition currently lacks approved treatments.
